Research To Practice | Oncology Videos

View Top 200 Chart

Back to Rankings Page

Science
**Research To Practice | Oncology Videos**

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

Latest Episodes:

Non-Hodgkin Lymphoma — Fourth Annual National General Medical Oncology Summit May 12, 2025

Show notes

Featuring perspectives from Dr Christopher Flower and Dr Krish Patel, including the following topics:

Role of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Non-Hodgkin Lymphoma (NHL) — Dr Patel (0:00)
Other Available and Emerging Novel Therapies for NHL — Dr Flowers (22:07)

CME information and select publications

Gynecologic Cancers — Fourth Annual National General Medical Oncology Summit May 11, 2025

Show notes

Featuring perspectives from Dr David M O'Malley and Dr Brian M Slomovitz, including the following topics:

Ovarian Cancer; HER2-Directed Therapy for Advanced Gynecologic Cancers — Dr O'Malley (0:00)
Endometrial Cancer and Cervical Cancer — Dr Slomovitz (23:38)

CME information and select publications

Non-Hodgkin Lymphoma — An Interview with Dr John P Leonard on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting May 10, 2025

Show notes

Featuring an interview with Dr John P Leonard, including the following topics:

First-line therapy for diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin and R-CHP; impact of DLBCL cell of origin (0:00)
Epcoritamab, glofitamab and other bispecific antibodies as initial therapy for large B-cell lymphoma (9:27)
Sequencing chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed/refractory (R/R) DLBCL (12:30)
Approved and investigational bispecific antibodies for the treatment of DLBCL (15:24)
Practical considerations for the administration of mosunetuzumab (22:03)
Tafasitamab combined with lenalidomide/rituximab as second-line treatment for follicular lymphoma (FL); third- and later-line therapy options (24:33)
Activity of Bruton tyrosine kinase inhibitors in FL and other non-Hodgkin lymphomas (31:27)
Risk of infection for patients receiving bispecific antibodies (33:23)
Chemotherapy-free regimens for the treatment of mantle cell lymphoma (MCL) (36:21)
Current role of transplant in the treatment algorithm for MCL; potential integration of bispecific antibodies into therapy for R/R disease (41:23)
Myths and misperceptions about the management of DLBCL, FL and MCL (47:29)

CME information and select publications

Non-Hodgkin Lymphoma — An Interview with Dr John P Leonard on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting (Companion Faculty Lecture) May 09, 2025

Show notes

Featuring a slide presentation and related discussion from Dr John P Leonard, including the following topics:

Five-year analysis of the POLARIX trial of polatuzumab vedotin with R-CHP for previously untreated diffuse large B-cell lymphoma (0:00)
Epcoritamab, glofitamab and other bispecific antibodies for large B-cell lymphoma (5:33)
Circulating tumor DNA as an early outcome predictor in patients with large B-cell lymphoma receiving second-line lisocabtagene maraleucel in the TRANSFORM study (16:44)
The bispecific antibodies mosunetuzumab and odronextamab as initial therapy for follicular lymphoma (FL) (19:27)
The Phase III inMIND trial of tafasitamab in combination with lenalidomide/rituximab for recurrent FL (22:58)
Updated results from studies of bispecific antibodies and chimeric antigen receptor T-cell therapy for relapsed/refractory FL (24:58)
Updates from the Phase III TRIANGLE and ECOG-ACRIN EA4151 trials on the role of autologous stem cell transplant in the treatment of previously untreated mantle cell lymphoma (MCL) (27:48)
Novel treatment approaches with Bruton tyrosine kinase inhibitors for patients with newly diagnosed MCL (30:53)

CME information and select publications

For Oncology Nurses: Prostate Cancer — Proceedings from the 2025 Annual ONS Congress May 08, 2025

Show notes

Featuring perspectives from Dr Rahul Aggarwal, Ms Monica Averia, Ms Kathleen D Burns and Dr William K Oh, including the following topics:

Introduction: Overview of Prostate Cancer (0:00)
Recent Advances in the Treatment of Nonmetastatic Prostate Cancer (8:36)
Treatment Approaches for Metastatic Hormone-Sensitive Prostate Cancer (30:01)
Current Role of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (47:41)
Current and Future Role of Radiopharmaceuticals in mCRPC (1:09:57)

NCPD information and select publications

Breast Cancer — Year in Review Series on Relevant New Datasets and Advances May 07, 2025

Show notes

Featuring perspectives from Prof Rebecca A Dent and Dr Nancy U Lin, including the following topics:

Introduction: A New Paradigm for Triple-Positive Breast Cancer? (0:00)
CDK4/6 Inhibitors for HR-Positive, HER2-Negative Breast Cancer (10:06)
Oral Selective Estrogen Receptor Degraders for HR-Positive, HER2-Negative Breast Cancer (21:17)
Treatment of PIK3CA/PTEN/AKT-Mutated Breast Cancer (31:34)
Antibody-Drug Conjugates (ADCs) for HR-Positive, HER2-Negative Breast Cancer (38:41)
ADCs for HER2-Positive Breast Cancer (46:30)
HER2-Targeting Tyrosine Kinase Inhibitors for HER2-Positive Breast Cancer (53:26)
ADCs for Advanced Triple-Negative Breast Cancer (58:29)

CME information and select publications

Breast Cancer | Nancy U Lin, MD May 06, 2025

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Breast Cancer | Faculty Presentation 2: HER2-Positive Breast Cancer and Triple-Negative Breast Cancer (TNBC) — Nancy U Lin, MD

CME information and select publications

Breast Cancer | Rebecca A Dent, MD, MSc May 06, 2025

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Breast Cancer | Faculty Presentation 1: HR-Positive Breast Cancer — Rebecca A Dent, MD, MSc

CME information and select publications

Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances May 04, 2025

Show notes

Featuring perspectives from Dr Jennifer R Brown and Prof Paolo Ghia, including the following topics:

Introduction: The Chronic Lymphocytic Leukemia (CLL) Experience — 2000 to 2025 (0:00)
Current Therapy Options with Covalent Bruton Tyrosine Kinase (BTK) Inhibitors (9:42)
Role of Venetoclax in the Treatment of CLL (26:52)
AMPLIFY Trial and Other Novel BTK Inhibitor and Bcl-2 Inhibitor Combination Strategies (32:29)
Noncovalent BTK Inhibitor Pirtobrutinib (46:47)
CAR T-Cell Therapy; Novel Agents (56:12)

CME information and select publications

Chronic Lymphocytic Leukemia | Jennifer R Brown, MD, PhD May 03, 2025

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Chronic Lymphocytic Leukemia | Faculty Presentation 2: Novel Agents and Combination Strategies — Jennifer R Brown, MD, PhD

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected